6833 — Sinco Pharmaceuticals Holdings Income Statement
0.000.00%
Last trade - 00:00
- HK$430.97m
- HK$488.83m
- CNY2.54bn
- 50
- 89
- 23
- 56
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,176 | 2,050 | 2,024 | 2,272 | 2,540 |
Cost of Revenue | |||||
Gross Profit | 220 | 274 | 365 | 306 | 323 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,113 | 1,905 | 1,828 | 2,154 | 2,426 |
Operating Profit | 63 | 145 | 197 | 118 | 114 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 43 | 136 | 167 | 99.3 | 99.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | 23.6 | 118 | 135 | 69.5 | 42.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 23.6 | 118 | 135 | 69.5 | 42.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 23.6 | 118 | 135 | 69.5 | 42.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.014 | 0.07 | 0.078 | 0.034 | 0.021 |
Dividends per Share |